Company / R&D Expense
Monopar Therapeutics R&D Expense History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$9.9M
FY2025
5-year range
$935.3K / $9.9M
FY2021-FY2025
Trend
+76.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $8M to $10M over the past 2 years.
Based on SEC 10-K filings.
$10M in FY2025.
Improved from $8M to $10M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, r&d expense increased 76.9% year-over-year.
- Lowest r&d expense in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 19.82 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $9.9M | +76.9% |
| FY2024 | $5.6M | -26.2% |
| FY2023 | $7.6M | +285.7% |
| FY2019 | $2.0M | +110.5% |
| FY2018 | $935.3K | +233.6% |
| FY2017 | $280.4K | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026